RT-002 by Revance Therapeutics for Upper Limb Muscle Spasticity: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RT-002 overview
RT-002 is under development for the treatment of spasmodic torticollis (cervical dystonia), upper limb spasticity and chronic migraine. It is administered by intramuscular route and a unspecified indication. The drug candidate is an injectable neurotoxin, purified botulinum toxin type A that targets synaptosomal-associated protein 25. It is developed based on TransMTS peptide technology.
It was under development for the treatment of plantar fasciitis and voice disorders.
Revance Therapeutics overview
Revance Therapeutics is a biotechnology company that focuses on the development, manufacturing and marketing novel botulinum toxin products. It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as chronic migraine, facial wrinkles and muscle disorders. Through the acquisition of HintMD, the company uses it platform to engage in the smart payment solution to process payments for their patients and provides subscription and pay-over-time solutions that support practices for the aesthetic treatment plans. The company is also advancing daxibotulinumtoxinA for injection (DAXI), an injectable formulation of botulinum toxin for the treatment of glabellar lines, cervical dystonia and plantar fasciitis. It employs its proprietary peptide excipient technology to advance the development of its novel neuromodulators portfolio. Revance Therapeutics is headquartered in Nashville, Tennessee, the US.
For a complete picture of RT-002’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#RT002 #Revance #Therapeutics #Upper #Limb #Muscle #Spasticity #Likelihood #Approval
